Top Markets
Coin of the day
Glenmark Life Sciences Limited Glenmark Life Sciences Limited

Glenmark Life Sciences Limited

GLS
Pozycja w akcjach #7698
Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011,... Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011, specializes in the creation, manufacturing, and distribution of high-value active pharmaceutical ingredients (APIs). These APIs are utilized across a wide array of chronic therapeutic areas. The company's diverse portfolio includes compounds for managing cardiovascular diseases (e.g., Olmesartan, Rosuvastatin, Amiodarone), central nervous system conditions (such as Oxcarbazepine, Topiramate, Lacosamide), and diabetes (including Glimepiride, Teneligliptin, Linagliptin). Additionally, they produce APIs for pain management (Etoricoxib, Lornoxicam), gastro-intestinal disorders, anti-infective treatments, respiratory ailments, and anti-emetic applications, featuring products like Atovaquone, Fluconazole, and Esomeprazole Magnesium. Beyond API production, Glenmark Life Sciences offers contract development and manufacturing (CDMO) solutions to numerous multinational and specialty pharmaceutical firms. Operating as a subsidiary of Glenmark Pharmaceuticals Limited, the company exports its products worldwide, reaching markets in Europe, North America, Latin America, and Japan.
Cena akcji
$12.18
Ostatnia synchronizacja: 2025-02-17
Kapitalizacja rynkowa
$1.49B
Zmiana (1 dzień)
4.21%
Zmiana (1 rok)
0.00%
Kraj
IN
Handel Glenmark Life Sciences Limited (GLS)

Kategoria

EPS dla Glenmark Life Sciences Limited (GLS)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy Glenmark Life Sciences Limited, obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla Glenmark Life Sciences Limited od 2026 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
Za mało danych dla podanych dat.